OncoMatch/Clinical Trials/NCT04857502
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Is NCT04857502 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 99mTc-based PSMA Imaging and Surgery Agent for prostate carcinoma.
Treatment: 99mTc-based PSMA Imaging and Surgery Agent — This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Prior therapy
Cannot have received: any PCa treatment
Exception: between study enrollment and surgery
Patients who started any PCa treatment between study enrollment and surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify